CD4 + T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials

Abstract

Background

International trials have shown that CD4⁺ T-cell-guided structured treatment interruptions (STI) of antiretroviral therapy (ART) lead to worse outcomes than continuous treatment. We simulated continuous ART and STI strategies with higher CD4⁺ T-cell interruption/reintroduction thresholds than those assessed in actual trials.

Methods

Using a model of HIV, we simulated cohorts of African adults with different baseline CD4⁺ T-cell counts (≤200; 201-350; and 351-500 cells/μl). We varied ART initiation criteria (immediate; CD4⁺ T-cell count <350 cells/μl or ≥350 cells/μl with severe HIV-related disease; and CD4⁺ T-cell count <200 cells/μl or ≥200 cells/μl with severe HIV- related disease), and ART interruption/reintroduction thresholds (350/250; 500/350; and 700/500 cells/μl). First-line therapy was non- nucleoside reverse transcriptase inhibitor (NNRTI)-based and second-line therapy was protease inhibitor (PI)-based.

Results

STI generally reduced life expectancy compared with continuous ART. Life expectancy increased with earlier ART initiation and higher interruption/reintroduction thresholds. STI reduced life expectancy by 48–69 and 11–30 months compared with continuous ART when interruption/reintroduction thresholds were 350/250 and 500/350 cells/μl, depending on ART initiation criteria. When patients interrupted/reintroduced ART at 700/500 cells/μl, life expectancies ranged from 2 months lower to 1 month higher than continuous ART. STI-related life expectancy increased with decreased risk of virological resistance after ART interruptions.

Conclusions

STI with NNRTI-based regimens was almost always less effective than continuous treatment, regardless of interruption/reintroduction thresholds. The risks associated with STI decrease only if patients start ART earlier, interrupt/reintroduce treatment at very high CD4⁺ T-cell thresholds (700/500 cells/μl) and use first-line medications with higher resistance barriers, such as PIs.

References

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

N Engl J Med 1998; 338: 853–860.

Mouton

, Alfandari

, Valette

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA.

AIDS 1997; 11: F101–F105.

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

CD4⁺ count-guided interruption of antiretroviral treatment.

N Engl J Med 2006; 355: 2283–2296.

Danel

, Moh

, Minga

CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.

Lancet 2006; 367: 1981–1989.

DART Trial Team.

Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl.

AIDS 2008; 22: 237–247.

Anglaret

, Messou

, Ouassa

Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire.

AIDS 2003; 17: 575–584.

Minga

, Danel

, Abo

Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire.

Bull World Health Organ 2007; 85: 116–123.

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

J Infect Dis 2008; 197: 1133–1144.

The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

Inferior clinical outcome of the CD4⁺ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4⁺ Cell counts and HIV RNA levels during follow-up.

J Infect Dis 2008; 197: 1145–1155.

10.

Cooper

D.A.

, Emery

, Cordery

D.V.

Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment.

J Infect Dis 2008; 197: 775. [Author reply 775–776].

11.

Freedberg

K.A.

, Losina

, Weinstein

M.C.

The cost effectiveness of combination antiretroviral therapy for HIV disease.

N Engl J Med 2001; 344: 824–831.

12.

Goldie

S.J.

, Yazdanpanah

, Losina

Cost-effectiveness of HIV treatment in resource-poor settings–the case of Cote d'Ivoire.

N Engl J Med 2006; 355: 1141–1153.

13.

Paltiel

A.D.

, Weinstein

M.C.

, Kimmel

A.D.

Expanded screening for HIV in the United States – an analysis of cost-effectiveness.

N Engl J Med 2005; 352: 586–595.

14.

Walensky

R.P.

, Paltiel

A.D.

, Losina

The survival benefits of AIDS treatment in the United States.

J Infect Dis 2006; 194: 11–19.

15.

Yazdanpanah

, Losina

, Anglaret

Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis.

AIDS 2005; 19: 1299–1308.

16.

Gold

M.R.

, Siegel

J.E.

, Russell

L.B.

, Weinstein

M.C.

(Editors). Cost Effectiveness in Health and Medicine. New York: Oxford University Press 1996.

17.

Danel

, Moh

, Anzian

Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa.

J Acquir Immune Defic Syndr 2006; 42: 29–35.

18.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. (Updated 7 August 2006. Accessed 8 January 2009.) Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.

19.

Mellors

J.W.

, Munoz

, Giorgi

J.V.

Plasma viral load and CD4⁺ lymphocytes as prognostic markers of HIV-1 infection.

Ann Intern Med 1997; 126: 946–954.

20.

Danel

, Moh

, Chaix

M.L.

Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African Adults.

J Infect Dis 2009; 199: 66–76.

21.

Messou

, Chaix

M.L.

, Gabillard

Strong association between medication possession ratio and early virological outcomes in adults on ART in Côte d'Ivoire. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 587.

22.

Losina

, Yazdanpanah

, Deuffic-Burban

The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

Antivir Ther 2007; 12: 543–551.

23.

Cole

S.R.

, Hernan

M.A.

, Robins

J.M.

Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Am J Epidemiol 2003; 158: 687–694.

24.

Silverberg

M.J.

, Neuhaus

, Bower

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

AIDS 2007; 21: 1957–1963.

25.

Moore

R.D.

, Keruly

J.C.

CD4⁺ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

Clin Infect Dis 2007; 44: 441–446.

26.

Le Moing

, Thiebaut

, Chene

Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/ml during treatment with antiretroviral drugs.

HIV Med 2007; 8: 156–163.

27.

Wester

C.W.

, Okezie

O.A.

, Thomas

A.M.

Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.

J Acquir Immune Defic Syndr 2007; 46: 318–322.

28.

Bolhaar

M.G.

, Karstaedt

A.S.

A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

Clin Infect Dis 2007; 45: 254–260.

29.

Ananworanich

, Gayet-Ageron

, Le Braz

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.

Lancet 2006; 368: 459–465.

30.

Maggiolo

, Ripamonti

, Gregis

, Quinzan

, Callegaro

, Suter

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.

AIDS 2004; 18: 439–446.

31.

Ruiz

, Paredes

, Gomez

Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

AIDS 2007; 21: 169–178.

32.

Pogány

, van Valkengoed

I.G.

, Prins

J.M.

Effects of active treatment discontinuation in patients with a CD4⁺ T-cell nadir greater than 350 cells/mm³: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).

J Acquir Immune Defic Syndr 2007; 44: 395–400.

33.

Skiest

D.J.

, Su

, Havlir

D.V.

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

J Infect Dis 2007; 195: 1426–1436.

34.

Phillips

A.N.

, Carr

, Neuhaus

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

Antivir Ther 2008; 13: 177–187.

35.

Maggiolo

, Airoldi

, Callegaro

CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.

AIDS 2009; 23: 799–807.

36.

Gallant

J.E.

, Staszewski

, Pozniak

A.L.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

JAMA 2004; 292: 191–201.

37.

Gallant

J.E.

, DeJesus

, Arribas

J.R.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

N Engl J Med 2006; 354: 251–260.

38.

Hammer

S.M.

, Eron

J.J.

Jr. , Reiss

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel.

JAMA 2008; 300: 555–570.

39.

Gilks

C.F.

, Crowley

, Ekpini

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Lancet 2006; 368: 505–510.

40.

Mackie

N.E.

, Fidler

, Tamm

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.

HIV Med 2004; 5: 180–184.

41.

Schweighardt

, Ortiz

G.M.

, Grant

R.M.

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.

AIDS 2002; 16: 2342–2344.

42.

Arnedo-Valero

, Garcia

, Gil

Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.

Clin Infect Dis 2005; 41: 883–890.

43.

Taylor

, Boffito

, Khoo

, Smit

, Back

Stopping antiretroviral therapy.

AIDS 2007; 21: 1673–1682.

44.

Fox

, Phillips

, Cohen

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

AIDS 2008; 22: 2279–2289.

45.

Médecins Sans Frontières. Untangling the web of price reductions. 11th edition. 2008. (Updated July 2008. Accessed 8 January 2009.) Available from http://www.msfaccess.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/Untanglingtheweb_July2008_English.pdf.

46.

French National Agency for Research on AIDS and Viral Hepatitis. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). (Updated 23 September 2009. Accessed 9 November 2009.) Available from http://clinicaltrials.gov/ct2/show/NCT00495651?term=temprano&rank=1.